安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Sorcero Secures $42. 5M Series B Financing Led by NewSpring . . .
Sorcero Secures $42 5M Series B Financing Led by NewSpring Capital to Scale Its AI Platform, Accelerate Expansion Across Life Sciences Agentic AI platform serves one-third of top 30 global pharma companies, delivering 18x faster insights and turning medical evidence into a driver for physician and patient adoption of novel therapies
- Sorcero raises $42. 5M for agentic AI pharma marketing - Axios
Sorcero, an agentic AI platform for the pharmaceutical industry, raised a $42 5 million Series B, CEO Dipanwita Das tells Axios Pro Why it matters: A growing group of startups is harnessing AI to help drug companies develop and sell new medicines
- Sorcero Secures $42. 5M Series B - vcnewsdaily. com
Sorcero, the AI-powered intelligence platform for life sciences, announced $42 5 million in Series B financing led by NewSpring Growth, NewSpring Capital's dedicated growth equity strategy that invests in fast-growing, industry-transforming technology companies They are joined by Leawood Venture Capital and Blu Ventures, bringing the company's total capital raised to $59 million The latest
- Techmeme: Sorcero, which makes AI agents for pharmaceutical . . .
Sorcero, which makes AI agents for pharmaceutical companies to market new medications, raised a $42 5M Series B, bringing its total funding to $59M — Sorcero, an agentic AI platform for the pharmaceutical industry, raised a $42 5 million Series B, CEO Dipanwita Das tells Axios Pro
- Sorcero - Startup Details
About Sorcero Sorcero makes AI agents for pharmaceutical companies to market new medications
- The Sorcero Pre-Series B Opportunity - by Wassim Matar
Pre-Series B, Sorcero's Clarity platform is experiencing rapid adoption by the leading life sciences companies in the $42 billion life sciences analytics market growing at a 29% CAGR Sorcero enables life sciences companies to make augmented data-driven decisions around how they retain and expand market share for their most valuable drugs, while improving patient outcomes
|
|
|